Demant proposes partial Oticon Medical divestment to ease competition concerns
An analyst at investment bank ABG assesses that Demant has a tough nut to crack in closing the Oticon Medical divestment as originally envisioned.
by albert rønning-andersson, translated by daniel pedersen
Demant is now purposely targeting a partial divestment of its surgical division, Oticon Medical, to Australia-based Cochlear, after the would-be buyer has pled for this case in response to the UK Competition and Markets Authority (CMA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
